Cerity Partners
BIO icon

Cerity Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cerity Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Sell
1,481
-4,605
-76% -$1.31M ﹤0.01% 2521
2026
Q1 		$1.7M Buy
6,086
+635
+12% +$183K ﹤0.01% 1573
2025
Q4 		$1.65M Buy
5,451
+570
+12% +$178K ﹤0.01% 1453
2025
Q3 		$1.37M Sell
4,881
-499
-9% -$136K ﹤0.01% 1456
2025
Q2 		$1.3M Sell
5,380
-1,492
-22% -$353K ﹤0.01% 1411
2025
Q1 		$1.67M Sell
6,872
-607
-8% -$183K ﹤0.01% 1203
2024
Q4 		$2.5M Sell
7,479
-314
-4% -$107K 0.01% 1007
2024
Q3 		$2.61M Buy
7,793
+1,767
+29% +$561K 0.01% 969
2024
Q2 		$1.65M Sell
6,026
-1,723
-22% -$501K ﹤0.01% 998
2024
Q1 		$2.68M Buy
7,749
+6,858
+770% +$2.26M 0.01% 862
2023
Q4 		$288K Buy
+891
New +$279K ﹤0.01% 1543
2023
Q2 		– Sell
-953
Closed -$877K – 1675
2023
Q1 		$877K Buy
953
+115
+14% +$53.8K ﹤0.01% 1038
2022
Q4 		$352K Buy
838
+336
+67% +$136K ﹤0.01% 1090
2022
Q3 		$209K Buy
502
+65
+15% +$32.4K ﹤0.01% 1041
2022
Q2 		$216K Buy
+437
New +$228K ﹤0.01% 1050
2022
Q1 		– Sell
-371
Closed -$282K – 951
2021
Q4 		$282K Buy
+371
New +$278K ﹤0.01% 798
2019
Q2 		– Sell
-707
Closed -$216K – 494
2019
Q1 		$216K Buy
+707
New +$191K 0.01% 485

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Cerity Partners's BIO Position: Q2 2026 in Review

Cerity Partners reduced its Bio-Rad Laboratories Class A (BIO) stake by 76% in Q2 2026, selling an estimated $1.31M and leaving 1,481 shares worth $435K. The position accounts for ﹤0.01% of the portfolio, ranked #2521.

Cerity Partners first reported a position in BIO in Q1 2019 and has held it in 17 quarters since. The position peaked at $2.68M in Q1 2024. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Cerity Partners held 1,481 shares of Bio-Rad Laboratories Class A worth $435K as of Q2 2026.
  • Cerity Partners sold 4,605 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $1.31M.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2521 holding.
  • Cerity Partners first reported a position in Bio-Rad Laboratories Class A in Q1 2019 and has held it in 17 quarters since.
  • Cerity Partners's Bio-Rad Laboratories Class A position peaked at $2.68M in Q1 2024.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.